Clinical course and treatment details of matches for CT patients
UPN . | Sex/age, y . | % VH homology . | Binet stage at study . | Lymphocyte count higher than 50 × 109/L . | FISH karyotype . | Time to symptoms, mos . | Time to study entry, mos . | First-line therapy . | Second-line therapy . | Additional salvage therapy . | Outcome (follow-up from diagnosis) . | Cause of death . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 91PB024 | M/57 | 100 | C | Yes | 13q14 | 48 | 93 | Clb × 24 | COP × 2 | Flud × 12; COP × 1 | Dead (134) | CLL |
| 95PB021 | F/55 | 100 | C | Yes | 11q23 | 1 | 24 | COP × 7 | Flud × 7 | Idarubicine × 3; 2CDA × 2; FE × 1; Paclitaxel × 1 | Dead (37) | CLL |
| 95PB324 | M/54 | 100 | C | Yes | 6q21; 11q23; 13q14 | 5 | 17 | Clb × 5 | Flud × 1 | No | Dead (45) | CLL |
| 96PB959 | M/52 | 100 | C | Yes | 13q14 | 46 | 69 | Clb × 5 | Clb × 3 | COP × 1; CHOP × 4; DexaBEAM × 1; CY × 1 | Alive (100+) | ND |
| 98PB547 | M/59 | 100 | C | Yes | Normal | 1 | 0 | Flud × 6 | No | No | Alive (10+) | ND |
| 91PB084 | F/47 | 100 | C | Yes | Normal | 2 | 9 | Clb × 2 | Flud × 12 | Flud × 3; PmM × 5; Idarubicin × 2; COP × 2; 2CDA × 3; Paclitaxel × 1 | Dead (78) | CLL |
| 91LK1 | M/45 | 100 | C | Yes | 11q23 | 0 | 16 | Clb × 10 | COP × 7 | CY × 4; Flud × 1; IMVP16 × 2 | Dead (21) | CLL |
| 91PB079 | M/58 | 99.3 | C | No | Normal | 5 | 23 | Clb × 4 | COP × 4 | PmM × 4; Flud × 9; VP16 × 2; CHOP × 1 | Dead (66) | Pulmonary embolism |
| 93PB212 | F/61 | 98.6 | B | Yes | 11q23; 13q14 | 13 | 14 | COP × 3 | Idarubicine × 3 | Flud × 4; Clb × 4 | Alive (78+) | ND |
| 92PB198 | F/59 | 99.6 | B | Yes | Normal | 85 | 90 | Clb × 2 | Flud × 8 | Flud × 2; CD20 × 1; 2CDA × 1; pentostatin × 1 | Alive (166+) | ND |
| 96PB816 | M/58 | 100 | B | Yes | 13q14 | 51 | 53 | Flud × 2 | COP × 6 | Clb × 2; COP × 3; DexaBEAM × 1; Clb × 1; CY × 1 | Alive (85+) | ND |
| 91PB132 | M/56 | 99.5 | B | Yes | Normal | 1 | 12 | Clb × 3 | COP × 2 | Flud × 4 | Dead (34) | Infection |
| 93PB194 | M/55 | 100 | B | Yes | 11q23 | 1 | 2 | COP × 4 | Flud × 6 | Flud × 3; Clb × 4; FC × 2; CD20 × 4; Clb × 2; CHOP × 1; Bendamustin × 1 | Dead (70) | CLL |
| 93PB170 | F/58 | 100 | B | Yes | 11q23; + 12 | 1 | 3 | Clb × 3 | Flud × 6 | Flud × 5; FC × 4; Clb × 1; CD20 × 4; CHOP × 1; Vindesine × 1 | Dead (56) | CLL |
| 98PB909 | F/56 | 100 | B | Yes | 13q14 | 62 | 76 | Clb × 22 | No | No | Alive (123+) | ND |
| 95PB433 | M/56 | 100 | B | Yes | 6q21; 11q23; 13q14 | 1 | 44 | COP × 6 | Flud × 5 | Clb × 2; COP × 2; 2CDA × 2; COP × 2; CD20 × 4; CHOP × 2 | Dead (83) | CLL |
| 94PB125 | M/53 | 99.6 | B | Yes | 13q14 | 88 | 73 | Flud × 7 | CHOP × 6 | DexaBEAM × 2 | Alive (134+) | ND |
| 91PB140 | F/53 | 99.6 | B | Yes | 11q23; 13q14 | 1 | 20 | Clb × 3 | CHOP × 3 | COP × 3; PmM × 1; Flud × 4 | Dead (34) | CLL |
| 93PB091 | M/50 | 100 | B | Yes | 11q23; + 12 | 31 | 17 | Flud × 6 | Idarubicine × 2 | COP × 2; 2CDA × 3; Clb × 1 | Dead (64) | CLL |
| 95PB540 | M/60 | 100 | B | No | + 12 | 113 | 79 | Clb × 1 | No | No | Dead (119) | CLL |
| 91PB138 | M/51 | 100 | B | No | 11q23; 13q14 | 11 | 24 | COP × 3 | Flud × 6 | Flud × 6 | Dead (63) | CLL |
| 92PB195 | M/51 | 100 | B | No | + 12 | 1 | 1 | COP × 3 | 2CDA × 1 | Clb × 6; Flud × 2; 2CDA × 1; DexaBEAM × 1 | Alive (70+) | ND |
| 94PB156 | F/44 | 100 | B | No | + 12 | 2 | 1 | COP × 6 | Flud × 3 | DexaBEAM × 1; Flud × 3; FC × 2; MCP × 2; IMVP16 × 1 | Dead (49) | CLL |
| 91PB124 | F/49 | 99.5 | A | Yes | 11q23; 13q14 | 1 | 19 | COP × 3 | CHOP × 3 | Clb × 3; Flud × 3 | Dead (53) | CLL |
| 92PB073 | F/57 | 100 | A | Yes | Normal | 27 | 21 | Prednimustin × 3 | Flud × 6 | Flud × 1 | Dead (73) | CLL |
| 94PB068 | F/52 | 100 | A | Yes | 6q21; + 12 | 79 | 79 | Flud × 6 | Clb × 6 | Flud × 2 | Alive (143+) | ND |
| 98PB277 | M/58 | 100 | A | No | 11q23; 13q14 | NA | 0 | No | No | No | Alive (14+) | ND |
| 96PB515 | M/54 | 100 | A | No | 13q14 | NA | 15 | No | No | No | Alive (51+) | ND |
| 93PB142 | M/53 | 100 | A | No | 13q14 | 66 | 17 | Clb × 4 | Clb × 1 | No | Alive (86+) | ND |
| 94PB141 | M/59 | 90.8 | C | No | 13q14 | 107 | 107 | COP × 1 | Clb × 5 | No | Dead (152) | Meningitis |
| 95PB384 | M/52 | 97.1 | C | No | Normal | 1 | 41 | Clb × 4 | Flud × 6 | CHOP × 6; HAM × 2 | Dead (67) | CLL |
| 93PB103 | M/63 | 90.9 | B | Yes | 13q14 | NA | 103 | No | No | No | Alive (176+) | ND |
| 94PB169 | M/45 | 92.6 | B | Yes | 13q14 | 62 | 28 | Clb × 3 | No | No | Alive (86+) | ND |
| Prostate | ||||||||||||
| 93PB155 | M/54 | 87.5 | B | No | + 12 | 30 | 42 | COP × 1 | No | No | Dead (84) | cancer |
| 93PB165 | M/53 | 90.8 | B | No | + 12; 13q14 | 106 | 78 | Flud × 2 | No | No | Alive (145+) | ND |
| 96PB908 | M/52 | 91.4 | B | No | + 12 | 27 | 4 | Clb × 2 | No | No | Alive (35+) | ND |
| 98PB235 | Low | B | No | NA | 1 | No | No | No | Alive (18+) | ND | ||
| 96PB453 | F/61 | 94.3 | A | Yes | 13q14 | NA | 105 | No | No | No | Alive (143+) | ND |
| 91PB070 | F/49 | 94.2 | A | Yes | + 12 | 43 | 79 | Prednimustin × 3 | COP × 1 | Clb × 17 | Alive (175+) | ND |
| 98PB136 | F/57 | 90.1 | A | No | 13q14 | NA | 3 | No | No | No | Alive (19+) | ND |
| 95PB432 | F/57 | 92.3 | A | No | 13q14 | NA | 28 | No | No | No | Alive (75+) | ND |
| 94PB168 | F/54 | 95.5 | A | No | 13q14 | NA | 24 | No | No | No | Alive (85+) | ND |
| 96PB905 | M/48 | 96.6 | A | No | 13q14 | NA | 33 | No | No | No | Alive (65+) | ND |
| 97PB260 | F/47 | 94.5 | A | No | + 12 | NA | 0 | No | No | No | Alive (24+) | ND |
UPN . | Sex/age, y . | % VH homology . | Binet stage at study . | Lymphocyte count higher than 50 × 109/L . | FISH karyotype . | Time to symptoms, mos . | Time to study entry, mos . | First-line therapy . | Second-line therapy . | Additional salvage therapy . | Outcome (follow-up from diagnosis) . | Cause of death . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 91PB024 | M/57 | 100 | C | Yes | 13q14 | 48 | 93 | Clb × 24 | COP × 2 | Flud × 12; COP × 1 | Dead (134) | CLL |
| 95PB021 | F/55 | 100 | C | Yes | 11q23 | 1 | 24 | COP × 7 | Flud × 7 | Idarubicine × 3; 2CDA × 2; FE × 1; Paclitaxel × 1 | Dead (37) | CLL |
| 95PB324 | M/54 | 100 | C | Yes | 6q21; 11q23; 13q14 | 5 | 17 | Clb × 5 | Flud × 1 | No | Dead (45) | CLL |
| 96PB959 | M/52 | 100 | C | Yes | 13q14 | 46 | 69 | Clb × 5 | Clb × 3 | COP × 1; CHOP × 4; DexaBEAM × 1; CY × 1 | Alive (100+) | ND |
| 98PB547 | M/59 | 100 | C | Yes | Normal | 1 | 0 | Flud × 6 | No | No | Alive (10+) | ND |
| 91PB084 | F/47 | 100 | C | Yes | Normal | 2 | 9 | Clb × 2 | Flud × 12 | Flud × 3; PmM × 5; Idarubicin × 2; COP × 2; 2CDA × 3; Paclitaxel × 1 | Dead (78) | CLL |
| 91LK1 | M/45 | 100 | C | Yes | 11q23 | 0 | 16 | Clb × 10 | COP × 7 | CY × 4; Flud × 1; IMVP16 × 2 | Dead (21) | CLL |
| 91PB079 | M/58 | 99.3 | C | No | Normal | 5 | 23 | Clb × 4 | COP × 4 | PmM × 4; Flud × 9; VP16 × 2; CHOP × 1 | Dead (66) | Pulmonary embolism |
| 93PB212 | F/61 | 98.6 | B | Yes | 11q23; 13q14 | 13 | 14 | COP × 3 | Idarubicine × 3 | Flud × 4; Clb × 4 | Alive (78+) | ND |
| 92PB198 | F/59 | 99.6 | B | Yes | Normal | 85 | 90 | Clb × 2 | Flud × 8 | Flud × 2; CD20 × 1; 2CDA × 1; pentostatin × 1 | Alive (166+) | ND |
| 96PB816 | M/58 | 100 | B | Yes | 13q14 | 51 | 53 | Flud × 2 | COP × 6 | Clb × 2; COP × 3; DexaBEAM × 1; Clb × 1; CY × 1 | Alive (85+) | ND |
| 91PB132 | M/56 | 99.5 | B | Yes | Normal | 1 | 12 | Clb × 3 | COP × 2 | Flud × 4 | Dead (34) | Infection |
| 93PB194 | M/55 | 100 | B | Yes | 11q23 | 1 | 2 | COP × 4 | Flud × 6 | Flud × 3; Clb × 4; FC × 2; CD20 × 4; Clb × 2; CHOP × 1; Bendamustin × 1 | Dead (70) | CLL |
| 93PB170 | F/58 | 100 | B | Yes | 11q23; + 12 | 1 | 3 | Clb × 3 | Flud × 6 | Flud × 5; FC × 4; Clb × 1; CD20 × 4; CHOP × 1; Vindesine × 1 | Dead (56) | CLL |
| 98PB909 | F/56 | 100 | B | Yes | 13q14 | 62 | 76 | Clb × 22 | No | No | Alive (123+) | ND |
| 95PB433 | M/56 | 100 | B | Yes | 6q21; 11q23; 13q14 | 1 | 44 | COP × 6 | Flud × 5 | Clb × 2; COP × 2; 2CDA × 2; COP × 2; CD20 × 4; CHOP × 2 | Dead (83) | CLL |
| 94PB125 | M/53 | 99.6 | B | Yes | 13q14 | 88 | 73 | Flud × 7 | CHOP × 6 | DexaBEAM × 2 | Alive (134+) | ND |
| 91PB140 | F/53 | 99.6 | B | Yes | 11q23; 13q14 | 1 | 20 | Clb × 3 | CHOP × 3 | COP × 3; PmM × 1; Flud × 4 | Dead (34) | CLL |
| 93PB091 | M/50 | 100 | B | Yes | 11q23; + 12 | 31 | 17 | Flud × 6 | Idarubicine × 2 | COP × 2; 2CDA × 3; Clb × 1 | Dead (64) | CLL |
| 95PB540 | M/60 | 100 | B | No | + 12 | 113 | 79 | Clb × 1 | No | No | Dead (119) | CLL |
| 91PB138 | M/51 | 100 | B | No | 11q23; 13q14 | 11 | 24 | COP × 3 | Flud × 6 | Flud × 6 | Dead (63) | CLL |
| 92PB195 | M/51 | 100 | B | No | + 12 | 1 | 1 | COP × 3 | 2CDA × 1 | Clb × 6; Flud × 2; 2CDA × 1; DexaBEAM × 1 | Alive (70+) | ND |
| 94PB156 | F/44 | 100 | B | No | + 12 | 2 | 1 | COP × 6 | Flud × 3 | DexaBEAM × 1; Flud × 3; FC × 2; MCP × 2; IMVP16 × 1 | Dead (49) | CLL |
| 91PB124 | F/49 | 99.5 | A | Yes | 11q23; 13q14 | 1 | 19 | COP × 3 | CHOP × 3 | Clb × 3; Flud × 3 | Dead (53) | CLL |
| 92PB073 | F/57 | 100 | A | Yes | Normal | 27 | 21 | Prednimustin × 3 | Flud × 6 | Flud × 1 | Dead (73) | CLL |
| 94PB068 | F/52 | 100 | A | Yes | 6q21; + 12 | 79 | 79 | Flud × 6 | Clb × 6 | Flud × 2 | Alive (143+) | ND |
| 98PB277 | M/58 | 100 | A | No | 11q23; 13q14 | NA | 0 | No | No | No | Alive (14+) | ND |
| 96PB515 | M/54 | 100 | A | No | 13q14 | NA | 15 | No | No | No | Alive (51+) | ND |
| 93PB142 | M/53 | 100 | A | No | 13q14 | 66 | 17 | Clb × 4 | Clb × 1 | No | Alive (86+) | ND |
| 94PB141 | M/59 | 90.8 | C | No | 13q14 | 107 | 107 | COP × 1 | Clb × 5 | No | Dead (152) | Meningitis |
| 95PB384 | M/52 | 97.1 | C | No | Normal | 1 | 41 | Clb × 4 | Flud × 6 | CHOP × 6; HAM × 2 | Dead (67) | CLL |
| 93PB103 | M/63 | 90.9 | B | Yes | 13q14 | NA | 103 | No | No | No | Alive (176+) | ND |
| 94PB169 | M/45 | 92.6 | B | Yes | 13q14 | 62 | 28 | Clb × 3 | No | No | Alive (86+) | ND |
| Prostate | ||||||||||||
| 93PB155 | M/54 | 87.5 | B | No | + 12 | 30 | 42 | COP × 1 | No | No | Dead (84) | cancer |
| 93PB165 | M/53 | 90.8 | B | No | + 12; 13q14 | 106 | 78 | Flud × 2 | No | No | Alive (145+) | ND |
| 96PB908 | M/52 | 91.4 | B | No | + 12 | 27 | 4 | Clb × 2 | No | No | Alive (35+) | ND |
| 98PB235 | Low | B | No | NA | 1 | No | No | No | Alive (18+) | ND | ||
| 96PB453 | F/61 | 94.3 | A | Yes | 13q14 | NA | 105 | No | No | No | Alive (143+) | ND |
| 91PB070 | F/49 | 94.2 | A | Yes | + 12 | 43 | 79 | Prednimustin × 3 | COP × 1 | Clb × 17 | Alive (175+) | ND |
| 98PB136 | F/57 | 90.1 | A | No | 13q14 | NA | 3 | No | No | No | Alive (19+) | ND |
| 95PB432 | F/57 | 92.3 | A | No | 13q14 | NA | 28 | No | No | No | Alive (75+) | ND |
| 94PB168 | F/54 | 95.5 | A | No | 13q14 | NA | 24 | No | No | No | Alive (85+) | ND |
| 96PB905 | M/48 | 96.6 | A | No | 13q14 | NA | 33 | No | No | No | Alive (65+) | ND |
| 97PB260 | F/47 | 94.5 | A | No | + 12 | NA | 0 | No | No | No | Alive (24+) | ND |
UPN indicates unique patient number; M, male; Clb, chlorambucil with or without prednisolone; COP, cyclophosphamide, vincristine, prednisolone; Flud, fludarabine; F, female; 2CDA, 2-chlor-desoxyadenosine; FE, fludarabine, epirubicine; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; ND, not dead; DexaBEAM, dexamethason (Dexa), carmustin, etoposide (VP16), Ara-C, melphalan; CY, cyclophosphamide; PmM, prednimustin, mitoxantron; IMVP16, ifosfamide, methotrexate, VP16; VP16, etoposide; CD20, rituximab; FC, fludarabine, CY; MCP, mitoxantron, Clb, prednisolone; NA, not applicable; and HAM, high-dose ara-C, mitoxantron.